MOBILE HEALTH APP TO MITIGATE THE METABOLIC EFFECTS OF ANDROGEN DEPRIVATION THERAPY: A RANDOMIZED PILOT TRIAL IN MEN NEWLY TREATED WITH ANDROGEN DEPRIVATION THERAPY

This research study seeks to develop and evaluate a mobile health app which aims to provide
patients who are about to initiate androgen deprivation therapy for prostate cancer with an
exercise program and better eating habits.

Inclusion Criteria:

Phase 1

- All recruited participants must have owned a smartphone for >1 year

- English-speaking.

- Patients with prostate cancer aged between 40-75 years will be considered.

- No specific timeframe after prostate cancer diagnosis will be required for these
patients.

- No limitations regarding their disease characteristics will be imposed (e.g.
metastatic disease).

- Patients may or may not be currently receiving treatment Staff members will be
recruited from

- Dana-Farber Cancer Institute Department of Medical Oncology,

- Brigham and Women's Hospital, Department of Surgery. Staff members aged between 40-75
years old will be considered. Phase 2

- Men diagnosed with prostate cancer presenting to DF/BWHCC

- About to initiate ADT for the first time will be considered.

- Age range 40-75-years

- The ability to walk 400 m

- Medical clearance from their primary physician

- English speaking

- Cognitively alert

- Literate

- Ability to read or hear with or without contacts/glass and hearing aid

- Ownership of a smartphone for >1yr

Exclusion Criteria:

- Men who have been under a rigorous structured exercise regime, such as individuals who
engage in more than 900 minutes of moderate physical activity per week in the last 6
months will not be considered

- Post-ADT treatment

- Planned systemic chemotherapy

- Planned treatment with abiraterone or enzalutamide

- Bone metastases

- Acute illness

- Any musculoskeletal, cardiovascular, or neurologic disorders that could inhibit or put
them at risk from exercising

- Subordinates to the PI